{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:56:29Z","timestamp":1795132589908,"version":"4.10.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.04.067","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T07:26:49Z","timestamp":1622273209000},"page":"4231-4237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice"],"prefix":"10.1016","volume":"39","author":[{"given":"Debra","family":"McGuinness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-6208","authenticated-orcid":false,"given":"Robin M.","family":"Kaufhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-103X","authenticated-orcid":false,"given":"Michael A","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-7747","authenticated-orcid":false,"given":"William J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Giovarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-2645","authenticated-orcid":false,"given":"Yuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-7037","authenticated-orcid":false,"given":"Luwy","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2021.04.067_b0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD Lower Respiratory Infections Collaborators","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.067_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41479-018-0055-4","article-title":"Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review","volume":"10","author":"Zivich","year":"2018","journal-title":"Pneumonia (Nathan)"},{"issue":"1","key":"10.1016\/j.vaccine.2021.04.067_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3346\/jkms.2013.28.1.4","article-title":"Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance","volume":"28","author":"Song","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2021.04.067_b0020","first-page":"1","article-title":"Human B and T lymphocyte responses to vaccination with pneumococcal polysaccharides","volume":"15","author":"Heilmann","year":"1990","journal-title":"APMIS Suppl"},{"issue":"9","key":"10.1016\/j.vaccine.2021.04.067_b0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1592\/phco.2005.25.9.1193","article-title":"Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention","volume":"25","author":"Bridy-Pappas","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.vaccine.2021.04.067_b0030","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/IAI.67.9.4862-4869.1999","article-title":"B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity","volume":"67","author":"McCool","year":"1999","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2021.04.067_b0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri1394","article-title":"Neonatal adaptive immunity comes of age","volume":"4","author":"Adkins","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.04.067_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype Replacement Study, Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"issue":"36","key":"10.1016\/j.vaccine.2021.04.067_b0045","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.vaccine.2019.05.003","article-title":"Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)","volume":"37","author":"LeBlanc","year":"2019","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2021.04.067_b0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >\/=65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2021.04.067_b0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults >\/=65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"45","key":"10.1016\/j.vaccine.2021.04.067_b0060","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"36","author":"Greenberg","year":"2018","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2021.04.067_b0065","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2019.08.048","article-title":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults","volume":"37","author":"Thompson","year":"2019","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.04.067_b0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.04.067_b0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6 Suppl 4","key":"10.1016\/j.vaccine.2021.04.067_b0080","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.amepre.2015.09.008","article-title":"Pneumococcal Disease Prevention Among Adults: Strategies for the Use of Pneumococcal Vaccines","volume":"49","author":"Pilishvili","year":"2015","journal-title":"Am J Prev Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.04.067_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131494","article-title":"Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany","volume":"10","author":"van der Linden","year":"2015","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.vaccine.2021.04.067_b0090","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.vaccine.2016.03.058","article-title":"A. Canadian Antimicrobial Resistance, Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F","volume":"34","author":"Golden","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.04.067_b0095","first-page":"648","article-title":"Sp, Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study, Lancet","volume":"5","author":"Savulescu","year":"2017","journal-title":"Respir Med"},{"issue":"45","key":"10.1016\/j.vaccine.2021.04.067_b0100","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults >\/=50 years of age","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2021.04.067_b0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.vaccine.2016.12.055","article-title":"Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain","volume":"35","author":"Caro-Aguilar","year":"2017","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2021.04.067_b0110","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1016\/j.vaccine.2011.09.078","article-title":"Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model","volume":"29","author":"Skinner","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.04.067_b0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.04.067_b0120","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/CVI.05252-11","article-title":"Establishment of a new human pneumococcal standard reference serum, 007sp","volume":"18","author":"Goldblatt","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.04.067_b0125","doi-asserted-by":"crossref","DOI":"10.4155\/bio-2020-0024","article-title":"Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.04.067_b0130","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.04.067_b0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/INF.0000000000002522","article-title":"Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants","volume":"39","author":"Xie","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"49","key":"10.1016\/j.vaccine.2021.04.067_b0140","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1016\/j.vaccine.2013.09.073","article-title":"Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose","volume":"31","author":"van Westen","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.04.067_b0145","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/CVI.00248-12","article-title":"Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine","volume":"19","author":"Simell","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.04.067_b0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/IAI.00768-10","article-title":"Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations","volume":"79","author":"Park","year":"2011","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.04.067_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0684.2011.00512.x","article-title":"A rhesus macaque model of Streptococcus pneumoniae carriage","volume":"41","author":"Philipp","year":"2012","journal-title":"J Med Primatol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.04.067_b0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1128\/IAI.69.1.336-344.2001","article-title":"Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B","volume":"69","author":"Sun","year":"2001","journal-title":"Infect Immun"},{"issue":"33","key":"10.1016\/j.vaccine.2021.04.067_b0165","doi-asserted-by":"crossref","first-page":"27885","DOI":"10.1074\/jbc.M112.380451","article-title":"Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal serotype","volume":"287","author":"Calix","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2021.04.067_b0170","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/IAI.71.5.2956-2959.2003","article-title":"Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model","volume":"71","author":"Jakobsen","year":"2003","journal-title":"Infect Immun"},{"issue":"41","key":"10.1016\/j.vaccine.2021.04.067_b0175","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.04.067_b0180","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1128\/JCM.00839-10","article-title":"Cross-reactivity of current serogroup 6 factor sera from Statens Serum Institut with the recently described pneumococcal serotype 6d","volume":"48","author":"Bratcher","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"22","key":"10.1016\/j.vaccine.2021.04.067_b0185","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.vaccine.2010.03.033","article-title":"Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization","volume":"28","author":"Licciardi","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2021.04.067_b0190","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1128\/CVI.00184-07","article-title":"Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C","volume":"14","author":"Rajam","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.04.067_b0195","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.04.067_b0200","article-title":"Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age","author":"Hurley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.04.067_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world","volume":"13","author":"Cui","year":"2017","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:00:08Z","timestamp":1759402808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":41,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X21005491"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}